Clinical Trials
21 trialsNCT06422806 2026-06-05
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04541108 2026-05-22
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Phase EARLY_PHASE1 Active not recruiting
NCT06113809 2026-05-22
Palbociclib and Pembrolizumab in Sarcoma
University of Iowa
Phase 1 Recruiting
NCT06789172 2026-05-22
INVOKE
Epkin
Phase 1 Recruiting
NCT07089992 2026-05-14
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04214067 2026-05-13
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05492682 2026-05-12
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase 1 Recruiting
NCT06898970 2026-05-08
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
Phase 2 Active not recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03914612 2026-05-04
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04483778 2026-04-28
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT05156268 2026-04-27
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03414229 2026-04-23
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04332874 2026-04-23
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05732831 2026-04-21
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07283731 2026-04-17
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT03197506 2026-03-25
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Phase 2 Active not recruiting
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting